ClinicalTrials.gg
CompletedNCT04561271RPASPUpdated Nov 17, 2026

Feasability of Foot Reflexology to Alleviate Anxiety in Palliative Care Unit (RPASP)

An interventional study of foot reflexology and toucher massage in End Stage Disease, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 17, 2026Now CompletedResults publication added+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary purpose of the study is to know if foot reflexology can be accepted by patients hospitalized in palliative unit care (assessed by the number of patient who accept to participate), and if it is feasible (assessed by the realization of one session in normal condition : duration of 15-20 min, in supine position/seated or half-seated position).The investigators make the hypothesis that patients will accept to receive foot reflexology, and maybe feel less anxious after one session.

Read the detailed description

The patients will receive an informative content about the study and will have 24 hours of reflexion. If they accept to participate to the study, they will be randomised in one of the two groups : foot reflexology or "toucher massage" (for those randomised in the "toucher massage" group, a session of foot reflexology will be proposed in a second time). The investigators will assess the level of anxiety, the quality of the sleep and the pain using the ESAS scale, before and after the session. 24 hours after the session, they will be interviewed about what they felt with the session. The investigators will also have a look on the anxiolytic and antagic medication they consume before and after the session.

02

Conditions studied

  • End Stage Disease

Browse trials for

Keywords

  • Palliative care
  • Foot reflexology
  • Anxiety
  • Acceptability
  • Feasability
03

In context

Anxiety Disorders Unverified

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

This study's enrollment of 30 is below the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult able to give consent, man or woman, hospitalized in palliative care unit, with vigilance criteria from +1 to -3 on the Richmond scale.
  • Affiliated to Social Security

Exclusion criteria

Exclusion Criteria:

  • Painfull bone on the feet
  • foot amputation
  • foot bedsore
  • peripheral distal neuropathy, trouble of foot sensibility
  • agonic or pre agonic state
  • Patients under juridical protection
  • Refusal to participate to the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    foot reflexology

    patients will receive one session of foot reflexology with a nurse who received a specific formation. The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. The technique consists in stimulating reflex zones of foot, each zone corresponding to a specific organ. Almond oil will be used. The session is accompanied by relaxing music

    Other: foot reflexology

  • Sham comparator
    toucher massage

    patients will receive one session of toucher massage with a nurse (this technique is taught during the formation of every nurse in palliative care units). The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. It consists in a simple massage and effleurage, with fluid and progressive movements. Almond oil will be used. The session is accompanied by relaxing music.

    Other: toucher massage

Interventions

  • Otherfoot reflexology

    Patients will receive one session of foot reflexology with a nurse who received a specific formation. The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. A neutral oil will be used. The technique associates specific movements of foot reflexology. The session is accompanied by relaxing music.

  • Othertoucher massage

    one session of toucher massage with a nurse (this technique is taught during the formation of every nurse in palliative care units). The session lasts 15 to 20 minutes, patients seated, half seated or in supine position. It consists in a simple massage and effleurage, with fluid and progressive movements. Almond oil will be used. The session is accompanied by relaxing music.

06

What researchers measure

Primary outcomes

  1. acceptability of foot reflexology in palliative care unit

    the acceptability will be assessed by the number of patient who accept to participate to the study

    Time frame: day 0

  2. feasibility of foot reflexology in palliative care unit

    The feasibility will be assessed by the conditions of realization of one session : for the study, the normal conditions will be : duration (15-20 min) and possibility for the patient to remain in the good position (supine position/seated or half-seated position).

    Time frame: day 0

Secondary outcomes

  1. Effects of foot reflexology on anxiety

    investigator will assess the anxiety, using the Edmonton Symptom Assessment System (ESAS scale), before and after the session. This scale permits the patient to choose a number from 0 to 10, 0 corresponding to the lowest level of anxiety, and 10 corresponding to the highest level of anxiety

    Time frame: Before the session (day 0) and 24 hours after

  2. Effects of foot reflexology on pain

    investigators will assess the pain using the Edmonton Symptom Assessment System (ESAS scale), before and after the session. This scale permits the patient to choose a number from 0 to 10, 0 corresponding to the lowest level of pain, and 10 corresponding to the highest level of pain

    Time frame: Before the session (day 0) and 24 hours after

  3. Effects of foot reflexology on sleep quality

    investigators will assess the sleep quality using the Edmonton Symptom Assessment System (ESAS scale), before and after the session. This scale permits the patient to choose a number from 0 to 10, 0 corresponding to the lowest level of tiredness, and 10 corresponding to the highest level of tiredness.

    Time frame: Before the session (day 0) and 24 hours after

  4. Effects of foot reflexology on anxiolytic intake

    investigators will write down the anxiolytic intake before the session, and until 24 hours after the session, using redcap software. There will be a "yes/no" question for "benzodiazepine" and "neuroleptic". If "yes" is chosen, there will be a free text box to be more specific

    Time frame: Before the session (day 0) and 24 hours after

  5. Effects of foot reflexology on pain killers intake

    investigators will write down the pain killer intake before the session, and until 24 hours after the session, using redcap software. There will be a "yes/no" question for "paracetamol", "weak opioids", "strong opioids" and "co-analgesics". If "yes" is chosen, there will be a free text box to be more specific.

    Time frame: Before the session (day 0) and 24 hours after

  6. patients' experience

    24 hours after the session, investigators will collect patients' experience and feeling about the session they undergone. Key words and verbatims will be reported on a free text box with redcap

    Time frame: day 1

07

Study locations

1 site
  • CHU de Clermont-Ferrand
    Clermont-Ferrand, 63000, France
08

References and documents

Publications

  • Marcolin ML, Tarot A, Lombardo V, Pereira B, Lander AV, Guastella V. The effects of foot reflexology on symptoms of discomfort in palliative care: a feasibility study. BMC Complement Med Ther. 2023 Feb 28;23(1):66. doi: 10.1186/s12906-023-03873-5. PubMed 36855141 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Jan 2022, 11 months.

Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's 11 months is close to that.

Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jul 2021 → Jan 2022 and completion Jul 2021 → Jan 2022.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2020
First posted
Sep 23, 2020
StartActual
Jan 11, 2021
Primary completionActual
Jan 4, 2022was Jul 2021
CompletionActual
Jan 4, 2022was Jul 2021
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 17, 2026
Primary completion
Jul 2021→Jan 4, 2022 (actual)
Nov 17, 2026
Study completion
Jul 2021→Jan 4, 2022 (actual)
Nov 17, 2026
Enrollment
43 (estimated)→30 (actual)
Nov 17, 2026
Publications
Results publication added: Marcolin ML, Tarot A, Lombardo V, Pereira B, Lander AV, Guastella V. The effects of foot reflexology on symptoms of discomfort in palliative care: a feasibilit… PubMed 36855141 ↗
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Status unknown→Completed
    Publications Results publication added: Marcolin ML, Tarot A, Lombardo V, Pereira B, Lander AV, Guastella V. The effects of foot reflexology on symptoms of discomfort in palliative care: a feasibilit… PubMed 36855141 ↗
    Primary completion Jul 2021→Jan 4, 2022 (now actual)
    Study completion Jul 2021→Jan 4, 2022 (now actual)
    Enrollment 43 (estimated)→30 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04561271
Responsible party
Sponsor
First posted
Sep 23, 2020
Start date
Jan 11, 2021
Primary completion
Jan 4, 2022
Completion
Jan 4, 2022
Last update
Nov 17, 2026

Study contacts

Virginie Guastella
principal investigator · University Hospital, Clermont-Ferrand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion